Longitudinal High-Throughput Sequencing of the T-Cell Receptor Repertoire Reveals Dynamic Change and Prognostic Significance of Peripheral Blood TCR Diversity in Metastatic Colorectal Cancer During Chemotherapy
Authors:
Open Access
- 12 January 2022
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 12, 743448
Abstract
Colorectal cancer (CRC) is a major cause of cancer mortality and morbidity. Despite advances in chemotherapy and targeted therapy, unsustainable clinical benefit was noted due to recurrence and therapy resistance. The immune status of the cancer patient may affect the effectiveness of disease treatments. The dynamic change in the T-cell receptor (TCR) repertoire might be a clinical parameter for monitoring treatment responses. In this study, we aimed to determine the characteristics and clinical significance of the TCR repertoire in patients with unresectable metastatic colorectal cancer (mCRC). Herein, we comprehensively profile 103 peripheral blood samples from 20 healthy controls and 16 CRC patients with a follow-up of 98 to 452 days to identify hypervariable rearrangements of the TCRα and TCRβ repertoires using high-throughput sequencing. We found that TCRα repertoires, TCRβ repertoires, and CDR3 clonotypes were altered in mCRC patients compared with healthy controls. The diversity of TCR repertoires and CDR3 clonotypes decreased in most mCRC patients after therapy. Furthermore, compared with baseline TCR diversity, patients whose TCR diversity dropped considerably during therapy had better treatment responses, including lower CEA and CA19-9 levels and smaller tumor sizes. TCR baseline diversity was also significantly associated with partial response (PR) status (odds ratio: 5.29, p = 0.04). In conclusion, the present study demonstrated the association between dynamic changes in TCR diversity during chemotherapy and clinical outcomes as well as the potential utility of the TCR repertoire in predicting the prognosis of cancer treatment.Keywords
Funding Information
- Chang Gung Medical Foundation (CMRPG3I0311, CMRPG3G2071, CMRPD1K0401)
- Chang Gung University (CLRPD1J0013, EMRPD1L0281)
- Ministry of Science and Technology, Taiwan (107-2314-B-182 -075 -MY3, MOST108-3017-F-182-001, 110-2314-B-182-046)
This publication has 35 references indexed in Scilit:
- Mortality of colorectal cancer in Taiwan, 1971–2010: temporal changes and age–period–cohort analysisInternational Journal of Colorectal Disease, 2012
- Cancer statistics, 2011CA: A Cancer Journal for Clinicians, 2011
- Normalization of T cell receptor repertoire diversity in patients with advanced colorectal cancer who responded to chemotherapyCancer Science, 2011
- Caution Is Required Before Recommending Routine Carcinoembryonic Antigen and Imaging Follow-Up for Patients With Early-Stage Colon CancerJournal of Clinical Oncology, 2009
- Dynamic monitoring the TCR CDR3 spectratypes in patients with metastatic CRC treated with a combination of bevacizumab, irinotecan, fluorouracil, and leucovorinCancer Immunology, Immunotherapy, 2009
- Many different Vβ CDR3s can reveal the inherent MHC reactivity of germline-encoded TCR V regionsProceedings of the National Academy of Sciences, 2009
- The CDR3 regions of an immunodominant T cell receptor dictate the 'energetic landscape' of peptide-MHC recognitionNature Immunology, 2005
- Carcinoembryonic Antigen Surge in Metastatic Colorectal Cancer Patients Responding to Oxaliplatin Combination Chemotherapy: Implications for Tumor Marker Monitoring and GuidelinesJournal of Clinical Oncology, 2003
- T-cell repertoire diversity and clonal expansions in normal and clinical samplesImmunology Today, 1995
- T-cell antigen receptor genes and T-cell recognitionNature, 1988